Lazertinib Disease Interactions
There are 4 disease interactions with lazertinib.
Lazertinib (applies to lazertinib) ILD/pneumonitis
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Interstitial Pneumonitis
Lazertinib, which is administered in combination with amivantamab, can cause interstitial lung disease (ILD)/pneumonitis. Patients should be monitored for worsening or new symptoms indicative of ILD/pneumonitis, such as dyspnea, cough or fever.
Lazertinib (applies to lazertinib) liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Lazertinib has not been studied in patients with severe hepatic impairment (total bilirubin greater than 3 x upper limit of normal and any AST).
Lazertinib (applies to lazertinib) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Lazertinib has not been studied in patients with severe renal dysfunction or end-stage renal disease (eGFR less than 30 mL/min).
Lazertinib (applies to lazertinib) vision disturbances
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Visual Defect/Disturbance
Lazertinib, which is administered in combination with amivantamab, can cause ocular toxicity, including keratitis. Patients should be monitored for new or worsening eye symptoms and referred promptly to an ophthalmologist.
Switch to professional interaction data
Lazertinib drug interactions
There are 376 drug interactions with lazertinib.
Report options
More about lazertinib
- lazertinib consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: EGFR inhibitors
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Tagrisso
Tagrisso (osimertinib) may be used to treat adults with non-small cell lung cancer (NSCLC) whose ...
Docetaxel
Docetaxel systemic is used for breast cancer, breast cancer, metastatic, gastric cancer, head and ...
Nivolumab
Nivolumab (brand name Opdivo) is an immunotherapy treatment that treats many cancers, such as ...
Paclitaxel
Paclitaxel systemic is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
